Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIMS: Dyslipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). As key regulators of lipoprotein metabolism, apolipoproteins (apos) are discussed as vascular risk factors. This study aimed to analyze associations of major plasma apos with coronary artery disease (CAD), peripheral artery disease (PAD) and carotid artery plaque (CAP) to elucidate their diagnostic potential in risk assessment. METHODS: ApoA-I, apoA-II, apoA-IV, apoB-100, apoC-I, apoC-III, apoE, and apoJ were simultaneously quantified in 3 μL EDTA-plasma by LC-MS/MS in a case-control subgroup of the Leipziger LIFE-Heart Study (N = 911). Confounder analysis with demographic, clinical covariates and serum lipids, cardiac, inflammatory, and hepatic markers were performed. Apos were associated with CAD, CAP, and PAD in a multivariate regression model. RESULTS: Fasting and statin therapy showed strongest effects on apo concentrations. Inverse correlations of HDL-related apos A-I, A-II, A-IV, and C-I were observed for troponin T and interleukin 6. Concentrations of apos A-II, B-100, C-I, and E were decreased under statin therapy. After adjustment for influencing factors and related lipids, only apoB-100 (odds ratio per one SD [OR], 1.39; 95% confidence interval [CI], 1.05-1.84) was independently associated with CAD while apoA-IV (OR, 0.74; 95% CI 0.58-0.95) indicated PAD. ApoB-100 (OR, 1.55; 95% CI, 1.18-2.04), apoC-III (OR, 1.30; 95% CI, 1.06-1.58), and apoE (OR, 1.34; 95% CI, 1.13-1.58) were associated with CAP. CONCLUSIONS: Triglyceride rich lipoproteins (TRLs) associated apos A-IV, B-100, C-III, and E are independently associated with stable ASCVD, providing further evidence for a potential role of TRLs in atherogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McQueen, M. J., Hawken, S., Wang, X., Ounpuu, S., Sniderman, A., Probstfield, J., Steyn, K., Sanderson, J. E., Hasani, M., Volkova, E., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61076-4 · Cited by 864
Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders
Mahley, R. W. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1427-y · Cited by 837
Jørgensen, A. B., Frikke-Schmidt, R., West, A. S., Grande, P., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs431 · Cited by 501
Apolipoprotein E isoforms and lipoprotein metabolism
Phillips, M. C. (2014) · IUBMB Life · doi:10.1002/iub.1314 · Cited by 328
Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Toth, P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s104369 · Cited by 237
Apolipoprotein C-III: from pathophysiology to pharmacology
Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.07.001 · Cited by 182
Sacks, F. M. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000146 · Cited by 168
Pencina, M. J., D’Agostino, R. B., Zdrojewski, T., Williams, K., Thanassoulis, G., Furberg, C. D., Peterson, E. D., Vasan, R. S., & Sniderman, A. D. (2015) · European Journal of Preventive Cardiology · doi:10.1177/2047487315569411 · Cited by 164
Agger, S. A., Marney, L. C., & Hoofnagle, A. N. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.152264 · Cited by 143
Quantification of seven apolipoproteins in human plasma by proteotypic peptides using fast LC‐MS/MS
Ceglarek, U., Dittrich, J., Becker, S., Baumann, F., Kortz, L., & Thiery, J. (2013) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201300034 · Cited by 38
Self-citation
Cited by
After another decade: LC–MS/MS became routine in clinical diagnostics
Seger, C., & Salzmann, L. (2020) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2020.03.004 · Cited by 301
Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond
Fuior, E. V., & Gafencu, A. V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235939 · Cited by 186
Siudut, J., Natorska, J., Wypasek, E., Wiewiórka, Ł., Ostrowska-Kaim, E., Wiśniowska-Śmiałek, S., Plens, K., Musialek, P., Legutko, J., & Undas, A. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.01.011 · Cited by 16
Begcevic Brkovic, I., Zöhrer, B., Scholz, M., Reinicke, M., Dittrich, J., Kamalsada, S., Baber, R., Beutner, F., Teren, A., Engel, C., et al. (2022) · Nutrients · doi:10.3390/nu14122474 · Cited by 13
“Previously, our group developed a rapid multiplexed LC-MS/MS assay for quantitative analysis of an apolipoprotein panel in human plasma and found total apoE plasma concentrations to be independently associated with stable atherosclerotic cardiovascular diseases in the Leipzig LIFE-Heart Study [21].”
MethodSelf-citation
Metadata
- Authors
- Dittrich, J., Beutner, F., Teren, A., Thiery, J., Burkhardt, R., Scholz, M., & Ceglarek, U.
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 281
- Pages
- 17-24
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W2899673450
- Cited by
- 41
- References
- 10
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease. https://app.cochat.ai/papers/10.1016/j.atherosclerosis.2018.11.006
- The paper
- Dittrich, J., Beutner, F., Teren, A., Thiery, J., Burkhardt, R., Scholz, M., & Ceglarek, U. (2019). Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2018.11.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.